Trial reportClinical cancer research : an official journal of the American Association for Cancer Research2017
Phase I Study of Epigenetic Priming with Azacitidine Prior to Standard Neoadjuvant Chemotherapy for Patients with Resectable Gastric and Esophageal Adenocarcinoma: Evidence of Tumor Hypomethylation as an Indicator of Major Histopathologic Response.
Registry-linked trialAbstract readClinical Trial, Phase IRandomized Controlled Trial
In one paragraph
Trial report in Clinical cancer research : an official journal of the American Association for Cancer Research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03941496 (Phase 1b/2a Safety and Immunogenicity of the DNMT Inhibitor Azacitidine During Anti-Tuberculosis Therapy), which is not on this map. Cited by 41 papers.
0numbers the graph read from it
0cells of the map it votes in
41citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
NCT03941496 phase1 / phase2withdrawnnot on this mapstarted 2022, after this paper: background citation
Phase 1b/2a Safety and Immunogenicity of the DNMT Inhibitor Azacitidine During Anti-Tuberculosis Therapy
Who cites it
41 citing papers in PubMed.
- Multimodal features and prognostic risk assessment in locally advanced gastric cancer patients following neoadjuvant therapy based on machine learning algorithms: a multicenter study.Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association · 2026Article
- Article
- DNA methyltransferase inhibitors in oncology: clinical progress, limitations and future directions.Epigenomics · 2026Review
- Advances in epigenetic therapy for esophageal cancer.Clinical epigenetics · 2026Review
- The inflammation-epigenetics axis in gastric cancer: Helicobacter-driven field defects, immune escape, and therapeutic frontiers.Frontiers in immunology · 2026Review
- Gastrointestinal inflammation and cancer: viral and bacterial interplay.Gut microbes · 2025Review
- The Interplay Between Esophageal Adenocarcinoma and Its Tumor Microenvironment: Toward Innovative Therapies.Cells · 2025Review
- The Role of DNA Methylation in Gastrointestinal Disease: An Expanded Review of Malignant and Nonmalignant Gastrointestinal Diseases.Gastroenterology · 2025Review
- Immune microenvironment features underlying the superior efficacy of neoadjuvant immunochemotherapy over chemotherapy in local advanced gastric cancer.Frontiers in immunology · 2025Article
- The Role of Epigenetic Mechanisms in the Treatment of GI Cancers.Current cancer drug targets · 2025Review
- Unveiling promising targets in gastric cancer therapy: A comprehensive review.Molecular therapy. Oncology · 2024Review
- Epigenetic modulation of cytokine expression in gastric cancer: influence on angiogenesis, metastasis and chemoresistance.Frontiers in immunology · 2024Review
- Targeting epigenetic deregulations for the management of esophageal carcinoma: recent advances and emerging approaches.Cell biology and toxicology · 2023Review
- Using Normalized Carcinoembryonic Antigen and Carbohydrate Antigen 19 to Predict and Monitor the Efficacy of Neoadjuvant Chemotherapy in Locally Advanced Gastric Cancer.International journal of molecular sciences · 2023Article
- Regulatory miRNAs in cancer cell recovery from therapy exposure and its implications as a novel therapeutic strategy for preventing disease recurrence.The Enzymes · 2023Article
- Signaling pathways and therapeutic interventions in gastric cancer.Signal transduction and targeted therapy · 2022Review
- MC180295 Inhibited Epstein-Barr Virus-Associated Gastric Carcinoma Cell Growth by Suppressing DNA Repair and the Cell Cycle.International journal of molecular sciences · 2022Article
- Identification of Immune Subtypes of Esophageal Adenocarcinoma to Predict Prognosis and Immunotherapy Response.Pharmaceuticals (Basel, Switzerland) · 2022Article
- DNA Methylation Malleability and Dysregulation in Cancer Progression: Understanding the Role of PARP1.Biomolecules · 2022Review
- Comparative genomic analysis of esophageal squamous cell carcinoma and adenocarcinoma: New opportunities towards molecularly targeted therapy.Acta pharmaceutica Sinica. B · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Bryan J SchneiderDivision of Hematology/Oncology, Department of Internal Medicine, Weill Cornell Medical College, New York, New York. bryansch@med.umich.edu.
Manish A ShahDivision of Hematology/Oncology, Department of Internal Medicine, Weill Cornell Medical College, New York, New York.
Kelsey KluteDivision of Hematology/Oncology, Department of Internal Medicine, Weill Cornell Medical College, New York, New York.
Allyson OceanDivision of Hematology/Oncology, Department of Internal Medicine, Weill Cornell Medical College, New York, New York.
Elizabeta PopaDivision of Hematology/Oncology, Department of Internal Medicine, Weill Cornell Medical College, New York, New York.
Nasser AltorkiDepartment of Thoracic Surgery, Weill Cornell Medical College, New York, New York.
Michael LiebermanDepartment of Surgery, Weill Cornell Medical College, New York, New York.
Andrew SchreinerDepartment of Pathology, Weill Cornell Medical College, New York, New York.
Rhonda YantissDepartment of Pathology, Weill Cornell Medical College, New York, New York.
Paul J ChristosDivision of Biostatistics and Epidemiology, Department of Healthcare Policy and Research, Weill Cornell Medical College, New York, New York.
Romae PalmerClinical Trials Office, Weill Cornell Medical College, New York, New York.
Daoqi YouMemorial Sloan-Kettering Cancer Center, New York, New York.
Agnes VialeMemorial Sloan-Kettering Cancer Center, New York, New York.
Pouneh KermaniDivision of Hematology/Oncology, Department of Internal Medicine, Weill Cornell Medical College, New York, New York.
Joseph M ScanduraDivision of Hematology/Oncology, Department of Internal Medicine, Weill Cornell Medical College, New York, New York.
Funding
Clinical and Translational Science CenterUL1TR000457 · NCATS · WEILL MEDICAL COLL OF CORNELL UNIV · PI IMPERATO-MCGINLEY, JULIANNE L · 2012 to 2016
$46.0MGenome-wide Identification of DNA Methylation Biomarkers in AMLR21CA159175 · NCI · WEILL MEDICAL COLL OF CORNELL UNIV · PI SCANDURA, JOSEPH MICHAEL · 2012 to 2013
$410kNCATS NIH HHS UL1 TR000457NCI NIH HHS R21 CA159175
Abstract
PubMed holds no abstract for this paper.
Indexed as
AdenocarcinomaAdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsAzacitidineCisplatinDNA MethylationDose-Response Relationship, DrugEpigenesis, GeneticEpirubicinEsophageal NeoplasmsFemaleFluorouracilHumansMaleAzacitidineCisplatinEpirubicinFluorouracilOrganoplatinum CompoundsOxaliplatinTumor Suppressor Proteins
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
NCT03941496ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.